Featuring perspectives from Dr Lisa A Carey and Dr Rita Nanda, including the following topics:

• Overview: Molecular basis of antibody-drug conjugate (ADC) toxicities — Sequencing of ADCs and mechanisms of resistance (0:00)
• Case: A woman in her late 60s with localized triple-negative breast cancer develops myocarditis during neoadjuvant therapy with chemotherapy/pembrolizumab — Richard Zelkowitz, MD (8:22)
• Case: A woman in her mid 70s with recurrent ER-negative, HER2-low, PD-L1-positive metastatic breast cancer (mBC) who experiences disease progression on nab paclitaxel/atezolizumab responds to sacituzumab govitecan — Ranju Gupta, MD (26:43)
• Case: A woman in her early 80s with recurrent ER-positive, HER2-low (IHC 1+) mBC experiences disease progression on trastuzumab deruxtecan (T-DXd), then receives datopotamab deruxtecan and develops pulmonary symptoms — Laila Agrawal, MD (32:11)
• Data Review: T-DXd (37:51)
• Case: A woman in her early 70s with recurrent ER-positive, HER2-low (IHC 1+) mBC, including bladder metastases, experiences disease progression after palbociclib/letrozole, then capivasertib/fulvestrant, then nab paclitaxel — Justin Favaro, MD, PhD (44:02)
• Case: A woman in her late 70s with ER-positive, HER2-low mBC who experiences disease progression after 1 year of ribociclib/letrozole receives sacituzumab govitecan — Erik Rupard, MD (55:19)

CME information and select publications

Featuring perspectives from Dr Yelena Y Janjigian, including the following topics:

• Introduction (0:00)
• Case: A man in his early 60s with a history of Barrett's esophagus presents with HER2-positive metastatic esophageal adenocarcinoma and a PD-L1 combined positive score (CPS) of 3 — Jennifer Yannucci, MD (10:20)
• Case: A man in his early 60s with multiregimen-recurrent HER2-positive gastroesophageal junction (GEJ) adenocarcinoma (claudin 18.2-positive, PD-L1 CPS 0) — Neil Morganstein, MD (14:53)
• Case: A woman in her early 80s with dementia and newly diagnosed mismatch repair-deficient, PD-L1-positive metastatic GEJ adenocarcinoma — Brian P Mulherin, MD (25:55)
• Case: A man in his mid 60s with localized HER2-negative GEJ cancer (PD-L1 CPS 2, claudin 18.2-positive) and residual disease after receiving neoadjuvant chemoradiation therapy and undergoing surgery — Stephen "Fred" Divers, MD (32:18)
• Case: A man in his early 80s with metastatic recurrence of esophageal adenocarcinoma and a PD-L1 total proportion score of 75% 2 years after resection of localized disease — Susmitha Apuri, MD (40:28)
• Case: A man in his mid 70s with claudin 18.2-positive metastatic esophageal adenocarcinoma who develops progressive toxicities with FOLFOX and zolbetuximab — Sean Warsch, MD (52:54)

CME information and select publications

Featuring perspectives from Dr Terence Friedlander and Dr Rana R McKay, including the following topics:

• Introduction (0:00)
• Prostate Cancer (1:44)
• Urothelial Bladder Cancer (29:18)

CME information and select publications

Featuring perspectives from Dr Luis Paz-Ares and Dr Misty Dawn Shields, including the following topics:

• Introduction: Tail on the Curve? (0:00)
• First-Line Chemoimmunotherapy (10:45)
• Maintenance Lurbinectedin (28:42)
• Second-Line Treatment, Tarlatamab (45:35)
• Ongoing Research (53:20)

CME information and select publications

Featuring perspectives from Dr Manish A Shah, moderated by Dr Stephen "Fred" Divers, including the following topics:

• Highlights and Principles of Management of Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma — Dr Shah (0:00)
• Case: A man in his early 50s with microsatellite instability-high localized esophageal adenocarcinoma — Dr Mulherin (15:24)
• Case: A woman in her late 60s with HER2-positive (IHC 3+) and HER2 TKD-mutant metastatic esophageal adenocarcinoma — Dr Warsch (25:34)
• Case: A woman in her early 70s with HER2-positive (IHC 3+), PD-L1-negative, CLDN18.2-negative metastatic gastric cancer — Dr Mulherin (28:15)
• Case: A woman in her early 70s with metastatic gastroesophageal junction adenocarcinoma (PD-L1 CPS 15) who begins treatment with FOLFOX/nivolumab and subsequently is found to have CLDN18.2 overexpression — Dr Lamar (35:23)
• Case: A man in his mid 40s with CLDN18.2-positive metastatic esophageal adenocarcinoma (PD-L1 10%) who receives mFOLFOX6 and zolbetuximab — Dr Yannucci (42:54)

CE information and select publications

Featuring perspectives from Dr Gottfried E Konecny, moderated by Dr Stephen "Fred" Divers, including the following topics:

• Updates in Ovarian Cancer (OC) 2025 — Dr Konecny (0:00)
• Case: A woman in her mid 50s with ovarian cancer and a PALB2 germline mutation — Dr Mulherin (17:15)
• Case: A woman in her early 60s with Stage IVB fallopian tube carcinoma and a BRCA2 germline mutation — Dr Yannucci (26:27)
• Case: A woman in her mid 60s with OC and a BRCA2 somatic mutation who develops cytopenias on maintenance olaparib — Dr Lamar (35:47)
• Case: A woman in her early 70s with HER2 IHC 2+, ER-expressing, FOLR1-positive OC — Dr Warsch (42:54)

CE information and select publications

Featuring perspectives from Dr Kerry Rogers, moderated by Dr Stephen "Fred" Divers, including the following topics:

• Chronic Lymphocytic Leukemia (CLL) — Dr Rogers (0:00)
• Case: A man in his mid 70s with CLL and a history of atrial fibrillation — Dr Lamar (13:08)
• Case: A fit man in his early 80s with IGHV-unmutated, TP53-mutant symptomatic CLL — Dr Mulherin (21:16)
• Case: A woman in her mid 80s with IGHV-mutated recurrent CLL who receives pirtobrutinib — Dr Warsch (32:41)
• Case: A woman in her late 70s with recurrent del(17p) CLL who receives venetoclax/obinutuzumab — Dr Yannucci (44:52)

CE information and select publications

Featuring perspectives from Dr Justin F Gainor, Dr Corey J Langer and Dr Misty Dawn Shields, moderated by Dr Stephen "Fred" Divers, including the following topics:

• Introduction (0:00)
• Targeted Therapy for Non-Small Cell Lung Cancer (NSCLC) — Dr Gainor, MD (5:32)
• Case: A woman in her mid 60s with ALK-mutant metastatic adenocarcinoma of the lung (PD-L1 TPS 70%) — Zanetta S Lamar, MD (17:59)
• Case: A woman in her mid 80s with EGFR exon 19-deleted adenocarcinoma of the lung with recurrence after 4 years of osimertinib — Jennifer Yannucci, MD (27:53)
• Case: A woman in her late 60s with HER2-mutant metastatic adenocarcinoma of the lung — Brian P Mulherin, MD (39:41)
• Case: A man in his early 70s with locally recurrent squamous cell carcinoma of the lung and a MET exon 14 skipping mutation — Sean Warsch, MD (46:39)
• Case: A woman in her early 70s with ROS1-mutant metastatic adenocarcinoma of the lung that responds to entrectinib and then to pembrolizumab/carboplatin/pemetrexed administered upon disease progression — Dr Yannucci (52:44)
• Nontargeted Therapy for NSCLC; Small Cell Lung Cancer — Dr Langer (58:16)
• Neoadjuvant, Perioperative and Adjuvant Anti-PD-1/PD-L1 Antibody-Based Approaches for Patients with Localized NSCLC — Dr Shields (1:14:14)
• Case: A man in his mid 60s with localized adenocarcinoma of the lung who receives neoadjuvant cisplatin/pemetrexed/pembrolizumab and achieves a pathologic complete response — Dr Mulherin (1:23:19)
• Case: A man in his early 60s with metastatic mixed adenosquamous NSCLC (PD-L1 TPS 50%) — Sunil Babu, MD (1:30:04)
• Case: A man in his late 50s diagnosed with extensive-stage small cell lung cancer who receives carboplatin/etoposide/durvalumab — Dr Warsch (1:34:07)

CE information and select publications

Featuring perspectives from Dr Jeremy S Abramson and Dr Loretta J Nastoupil, including the following topics:

• Overview of Chimeric Antigen Receptor (CAR) T-Cell Therapy (0:00)
• Potential Treatment Benefits of CAR T-Cell Therapy (13:31)
• Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome (28:13)
• Finding Information About CAR T-Cell Therapy; Clinical Trials (36:28)
• Financial Issues; Risk of Infection (42:02)
• Coping with Anxiety; Healing and Moving On (53:27)

CME information and select publications

Featuring an interview with Dr John V Heymach, including the following topics:

• Differentiating factors among various HER2 alterations in non-small cell lung cancer (NSCLC) (0:00)
• Activity of targeted agents across HER2 alterations in NSCLC (4:06)
• Available data with zongertinib and sevabertinib for HER2-mutant NSCLC (20:39)
• Case: A man in his late 40s with HER2-mutant NSCLC receives multiple lines of therapy, including trastuzumab deruxtecan (T-DXd) and zongertinib (29:23)
• Case: A woman in her mid 50s with HER2-mutant NSCLC receives zongertinib with durable response (34:23)
• Case: A woman in her late 50s with HER2-mutant NSCLC receives multiple lines of therapy, including sevabertinib and T-DXd (39:53)
• Investigational approaches in HER2-mutant NSCLC (46:31)

CME information and select publications

Featuring a slide presentation and related discussion from Dr John V Heymach, including the following topics:

• Overview of the biology and treatment landscape of HER2-mutant non-small cell lung cancer (NSCLC) (0:00)
• Datasets evaluating trastuzumab deruxtecan for HER2-mutant NSCLC (5:03)
• Clinical data with zongertinib for HER2-mutant NSCLC (6:35)
• Emerging data with sevabertinib for HER2-mutant NSCLC (14:41)
• Other investigational strategies being evaluated for HER2-mutant NSCLC (19:10)
• Summary of the current and future treatment landscape of HER2-mutant NSCLC (21:52)

CME information and select publications